27 May, 2017
A number of analysts have recently weighed in on the company.
Historically, if we have a peek at price target revisions, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)'s price target was revised by the analysts two weeks back on 04/25/17 to set its target price at $11.80 where its twelve month high target price was set at $14 and low at $11 while demonstrating the standard deviation of 1.30. Finally, Zacks Investment Research raised Aurinia Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, March 20th. Canaccord Genuity set a $10.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a "buy" rating in a research note on Saturday, March 11th.
2 analysts on average are expecting Aurinia Pharmaceuticals Inc.to report earnings of $-0.14 per share for the current quarter.
A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company.
Shares of Cenovus Energy Inc (USA) (NYSE:CVE) declined -3.76% to $9.21. Given that its average daily volume over the 30 days has been 9.57 million shares a day, this signifies a pretty significant change over the norm.
The volume of the particular stock is the shares bought and sold in a single trading day. Market Cap is also the figure use to determine company's size, as opposed to using sales or total asset figures. The 1-year High price of the stock is $0.54, while the 1-year low price is $1.74.
Aurinia Pharmaceuticals Inc. (AUPH) now has a Return on Assets (ROA) value of 0 Percent. Earnings, with 6 analysts believing the company would generate an Average Estimate of $-0.12. Street analysts have a consensus EPS projection of $-0.12 for the current quarter. Aurinia Pharmaceuticals had a negative net margin of 9,512.50% and a negative return on equity of 109.61%. The original version of this report can be read at https://www.chaffeybreeze.com/2017/05/26/aurinia-pharmaceuticals-inc-auph-posts-earnings-results-misses-expectations-by-0-08-eps-updated.html. If you are accessing this article on another publication, it was illegally copied and republished in violation of worldwide copyright and trademark law.
The number of shares now held by investors is 82.1 Million. Renaissance Technologies LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at $776,000. NEA Management Company LLC increased its position in Aurinia Pharmaceuticals by 18.2% in the first quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company's stock valued at $35,294,000 after buying an additional 740,740 shares in the last quarter. Morgan Stanley boosted its stake in shares of Aurinia Pharmaceuticals by 11,061.7% in the first quarter. Redmile Group LLC now owns 187,610 shares of the biotechnology company's stock valued at $565,000 after buying an additional 159,200 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $595,000.
Aurinia Pharmaceuticals Inc.is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity.
